Overview
Mitochondrial-targeting peptide that reduces oxidative stress and protects cells from damage. Shows promise for heart failure and neurodegenerative diseases.
Approval status across major regulatory agencies worldwide.
Mechanism of Action
Targets inner mitochondrial membrane cardiolipin, stabilizes electron transport chain, reduces reactive oxygen species production, protects cristae structure.
Stability & Storage
| Form | Storage Conditions | Shelf Life |
|---|---|---|
| Lyophilised (Freeze-Dried) |
Store at -20°C for long-term storage (24+ months). Stable at 2-8°C for up to 12 months. D-amino acids confer excellent stability. Protect from light. | 12 months |
| Reconstituted Solution |
After reconstitution with sterile saline, stable at 2-8°C for up to 30 days. Can be stored at room temperature for 7 days. pH stable between 4-8. | 30 days |
- Always store in original packaging until ready to use
- Protect from light, moisture, and temperature fluctuations
- Never refreeze after thawing
- Use proper sterile technique when reconstituting
- Discard if solution becomes cloudy or discolored
Target Information
- Mitochondrial membranes in all tissues
- particularly cardiac and neuronal
- Heart
- brain
- kidneys
- skeletal muscle
- retina
Pharmacokinetics: Half-Life by Administration Route
The biological half-life varies significantly depending on the route of administration. This affects dosing frequency and duration of action.
| Administration Route | Half-Life | Clinical Implications |
|---|---|---|
| Intravenous (IV) | Approximately 1-2 hours in plasma after IV infusion. Rapidly accumulates in mitochondria with prolon | Direct bloodstream entry, fastest onset, shortest duration |
| Subcutaneous (SC) | Approximately 2-3 hours after subcutaneous administration in preclinical models | Slower absorption, sustained release, most common route |
Note: Half-life values can vary between individuals based on factors including age, metabolism, kidney/liver function, and co-administered medications.
Molecular Structure
Amino Acid Sequence
2D Chemical Structure
Interactive 2D structure rendered from SMILES notation
3D Molecular Model
3D structure model will be available soon
Structure visualization powered by 3Dmol.js (integration pending)
Peptide Composition & Modifications
Amino Acid Composition
Terminus Modifications
Terminal modifications can protect against exopeptidase degradation and modulate biological activity.
Nomenclature
- Elamipretide
- Bendavia
- MTP-131
- D-Arg-Dmt-Lys-Phe-NH2
Dosage & Administration
Clinical trial doses: 0.25-40 mg IV daily
This information is for educational purposes only. Dosing should only be determined by a qualified healthcare provider based on individual patient needs and medical history.
Research & Clinical Status
Multiple Phase 2 clinical trials completed. Phase 3 trials ongoing for heart failure.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or medication. The information provided here is based on available scientific literature and may not be complete or up-to-date.